76Bio develops novel small molecule therapeutics targeting challenging protein-protein interactions (PPIs) implicated in disease. The company utilizes proprietary computational platforms to design and optimize highly selective inhibitors against historically undruggable targets. This approach aims to create first-in-class medicines for oncology and other serious conditions.
Funding
$22.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many life-threatening diseases are driven by specific proteins that contribute to disease progression. Traditional therapeutic approaches may not effectively eliminate these harmful proteins, limiting treatment efficacy.
Solution
76Bio is developing a new generation of targeted protein degraders designed to selectively eliminate disease-causing proteins. This approach aims to enhance the efficacy of treatments for patients with life-threatening diseases by directly removing the proteins responsible for driving disease progression. By targeting and degrading these proteins, 76Bio seeks to create transformational therapies with improved outcomes.
Target Audience
The primary target audience is patients suffering from life-threatening diseases and the healthcare providers who treat them.
Features
- Development of targeted protein degraders
- Focus on life-threatening diseases
- Aims to selectively eliminate harmful proteins
- Next-generation therapeutic approach